» Articles » PMID: 28970943

Towards Individualized Diagnostics of Biofilm-associated Infections: a Case Study

Overview
Date 2017 Oct 4
PMID 28970943
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Organized within biofilm communities, bacteria exhibit resistance towards a broad spectrum of antibiotics. Thus, one might argue that bacteria isolated from biofilm-associated chronic infections should be subjected to resistance profiling under biofilm growth conditions. Various test systems have been developed to determine the biofilm-associated resistance; however, it is not clear to what extent the in vitro results reflect the situation in vivo, and whether the biofilm-resistance profile should guide clinicians in their treatment choice. To address this issue, we used confocal microscopy in combination with live/dead staining, and profiled biofilm-associated resistance of a large number (>130) of clinical isolates from overall 15 cystic fibrosis patients. Our results demonstrate that in addition to a general non-responsiveness of bacteria when grown under biofilm conditions, there is an isolate-specific and antibiotic-specific biofilm-resistance profile. This individual resistance profile is independent on the structural properties of the biofilms. Furthermore, biofilm resistance is not linked to the resistance profile under planktonic growth conditions, or a mucoid, or small colony morphology of the tested isolates. Instead, it seems that individual biofilm structures evolve during biofilm-associated growth and are shaped by environment-specific cues. In conclusion, our results demonstrate that biofilm resistance profiles are isolate specific and cannot be deduced from commonly studied phenotypes. Further clinical studies will have to show the added value of biofilm-resistance profiling. Individualized diagnosis of biofilm resistance might lead to more rational recommendations for antimicrobial therapy and, thus, increased effectiveness of the treatment of chronically infected patients.

Citing Articles

Biofilm antimicrobial susceptibility testing: where are we and where could we be going?.

Coenye T Clin Microbiol Rev. 2023; 36(4):e0002423.

PMID: 37812003 PMC: 10732061. DOI: 10.1128/cmr.00024-23.


Transcriptional Profiling of Pseudomonas aeruginosa Infections.

Thoming J, Haussler S Adv Exp Med Biol. 2022; 1386:303-323.

PMID: 36258077 DOI: 10.1007/978-3-031-08491-1_11.


Azithromycin possesses biofilm-inhibitory activity and potentiates non-bactericidal colistin methanesulfonate (CMS) and polymyxin B against Klebsiella pneumonia.

Moshynets O, Baranovskyi T, Cameron S, Iungin O, Pokholenko I, Jerdan R PLoS One. 2022; 17(7):e0270983.

PMID: 35776759 PMC: 9249213. DOI: 10.1371/journal.pone.0270983.


Is More Tolerant Under Biofilm Than Under Planktonic Growth Conditions: A Multi-Isolate Survey.

Thoming J, Haussler S Front Cell Infect Microbiol. 2022; 12:851784.

PMID: 35295755 PMC: 8920030. DOI: 10.3389/fcimb.2022.851784.


A new BiofilmChip device for testing biofilm formation and antibiotic susceptibility.

Blanco-Cabra N, Lopez-Martinez M, Arevalo-Jaimes B, Martin-Gomez M, Samitier J, Torrents E NPJ Biofilms Microbiomes. 2021; 7(1):62.

PMID: 34344902 PMC: 8333102. DOI: 10.1038/s41522-021-00236-1.


References
1.
Yau Y, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M . Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2014; 14(2):262-6. DOI: 10.1016/j.jcf.2014.09.013. View

2.
Moskowitz S, Emerson J, McNamara S, Shell R, Orenstein D, Rosenbluth D . Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol. 2010; 46(2):184-92. PMC: 3479399. DOI: 10.1002/ppul.21350. View

3.
Hassett D, Cuppoletti J, Trapnell B, Lymar S, Rowe J, Yoon S . Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev. 2002; 54(11):1425-43. DOI: 10.1016/s0169-409x(02)00152-7. View

4.
Bals R, Hubert D, Tummler B . Antibiotic treatment of CF lung disease: from bench to bedside. J Cyst Fibros. 2011; 10 Suppl 2:S146-51. DOI: 10.1016/S1569-1993(11)60019-2. View

5.
Owlia P, Nosrati R, Alaghehbandan R, Lari A . Antimicrobial susceptibility differences among mucoid and non-mucoid Pseudomonas aeruginosa isolates. GMS Hyg Infect Control. 2014; 9(2):Doc13. PMC: 4141634. DOI: 10.3205/dgkh000233. View